Patent · US Active

Method of inhibiting ABCG2 and related treatments

US9937217B2 · kind B2 · utility

0Cited by

4References

9Claims

0Family size

Assignee

The United States of America, as represented by the Secretary, Department of Health and Human Services · US

Inventors

Curtis J. Henrich · Rockville, US
Heidi R. Bokesch · Frederick, US
Susan E. Bates · Bethesda, US
Robert W. Robey · Laurel, US
Suneet Shukla · Rockville, US
Suresh V. Ambudkar · Gaithersburg, US
Michael Dean · Frederick, US
James B. McMahon · Frederick, US

Key dates

Filing date	Aug 10, 2015
Grant date	Apr 10, 2018
Priority date	—
Expiry date	Aug 17, 2035

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/04
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are methods of enhancing the chemotherapeutic treatment of tumor cells, reducing resistance of a cancer cell to a chemotherapeutic agent, a method of inhibiting ABCG2 or MRP1 in a mammal afflicted with cancer, and a method of increasing the bioavailability of an ABCG2 substrate drug in a mammal. The methods comprise administering peliomycin and other compounds described herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.